Journavx is a drug owned by Vertex Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Journavx's patents will be open to challenges from 30 January, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 04, 2040. Details of Journavx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11834441 | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(15 years from now) | Active |
FDA has granted several exclusivities to Journavx. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Journavx, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Journavx.
Exclusivity Information
Journavx holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Journavx's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
US patents provide insights into the exclusivity only within the United States, but Journavx is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Journavx's family patents as well as insights into ongoing legal events on those patents.
Journavx's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Journavx's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 04, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Journavx Generics:
There are no approved generic versions for Journavx as of now.
About Journavx
Journavx is a drug owned by Vertex Pharmaceuticals Inc. Journavx uses Suzetrigine as an active ingredient. Journavx was launched by Vertex Pharms Inc in 2025.
Approval Date:
Journavx was approved by FDA for market use on 30 January, 2025.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Journavx is 30 January, 2025, its NCE-1 date is estimated to be 30 January, 2029.
Active Ingredient:
Journavx uses Suzetrigine as the active ingredient. Check out other Drugs and Companies using Suzetrigine ingredient
Dosage:
Journavx is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Prescription | ORAL |